Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Rectal Neoplasms 1Pancreatic cancer, adult 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Pancreatic Ductal 1

Interventions

Fluorouracil 21Oxaliplatin 17Leucovorin 17Bevacizumab 17Irinotecan 13Panitumumab 12Cetuximab 12IFL protocol 9Capecitabine 9pembrolizumab 7Radiotherapy 7Pemetrexed 5Gemcitabine 5labetuzumab 3conatumumab 3Cisplatin 3Carboplatin 3Albumin-Bound Paclitaxel 35,11-methenyltetrahydrohomofolate 3130-nm albumin-bound paclitaxel 3vatalanib 2trametinib 2spartalizumab 2pegfilgrastim 2ganitumab 2encorafenib 2dostarlimab 2Ramucirumab 2Paclitaxel 2Melphalan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Rectal Neoplasms × ensituximab × Clear all
NCT01040000 2017-08-04

QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer

Precision Biologics, Inc

Phase 1/2 Completed
94 enrolled
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡